Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in multiple ascending dose (MAD) cohort 3; safety, pharmacokinetic, and pharmacodynamic data expected Q4 2025CTA successfully submitted in Europe for Phase 1b clinical trial in female OTC heterozygotesNominated development candidate, CMP-SYNGAP-01, to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025American Society of Cell and Gene Therapy (ASGCT) oral presentations t ...

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase 1 clinical trial of CMP-CPS-001 in healthy volunteers to be presented CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulat ...

– Phase 1 clinical trial of CMP-CPS-001 in Urea Cycle Disorders (UCDs) ongoing, with dosing completed in two of four multiple ascending dose (MAD) cohorts; safety, pharmacokinetic, and pharmacodynamic data anticipated in Q4 2025 – Initiation of expansion into Phase 1b clinical trial in female OTC heterozygotes expected in Q2 2025 – Nomination of development candidate CMP-SYNGAP-01 to address SYNGAP1-related disorders; GLP toxicology studies expected to be initiated in 2025 CAMBRIDGE, Mass., March 27, 2025 ( ...

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression to restore healthy ...

Core Insights - CalAmp Corp. is no longer listed on Nasdaq and will participate in the STN East Conference on March 24, 2025 [1] - The company provides advanced solutions for GPS tracking, fleet optimization, and student safety, with over 1,000 school districts in the US and Canada utilizing its technology [2] - CalAmp aims to empower school districts with real-time data to enhance fleet efficiency and student safety [3] Company Overview - CalAmp offers flexible solutions for monitoring, tracking, and protecting vital assets, with over 10 million active edge devices and more than 220 approved or pending patents [5] - The company is recognized as a leader in telematics, providing innovative and dependable solutions for commercial and government organizations [5] Event Participation - At the STN East Conference, CalAmp Synovia will engage with transportation professionals to discuss industry trends and innovations [3] - Attendees at Booth 108 will have the opportunity to interact with CalAmp experts for insights into future student transportation technology [2][3]

Group 1 - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][4] - The company will participate in several upcoming investor conferences, including Oppenheimer's 35th Annual Healthcare Life Sciences Conference on February 12, 2025, and the Leerink Partners Global Healthcare Conference on March 10, 2025 [1][2] - CAMP4's proprietary RAP Platform™ allows for the mapping of regRNAs and the generation of therapeutic candidates aimed at treating over 1,200 genetic disorders where a modest increase in protein expression could be clinically meaningful [4] Group 2 - The company is developing disease-modifying treatments for a wide range of rare and prevalent genetic diseases, emphasizing the importance of increasing healthy protein levels for therapeutic benefits [4] - The upcoming presentations will be accessible via webcasts, with replays available for 30 days following the events [3]

Core Insights - CalAmp has integrated Okta Single Sign-On (SSO) into its iOn™ Fleet and Device Management applications, enhancing security and simplifying user access management [1][2] - The partnership with Okta aims to provide customers with improved security and efficient access management across CalAmp applications [2] Product Features - Users can log in once to access all CalAmp applications, reducing password fatigue and enhancing security with a single login [6] - Multi-Factor Authentication (MFA) via Okta adds an extra layer of protection against unauthorized access [6] - IT teams can manage and revoke user access from a single platform, improving operational efficiency and control [6] - Organizations can customize security policies for SSO enforcement to meet specific needs [6] - Role-Based Access Control (RBAC) allows management of user permissions across iOn™ and Device Management, ensuring appropriate access to tools and data [6] Company Overview - CalAmp provides telematics and connected intelligence solutions, helping organizations monitor, track, and protect vital assets [3] - The company has over 10 million active edge devices and holds 220+ approved or pending patents, positioning itself as a leader in the telematics industry [3]

Company Overview - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to upregulate gene expression and restore healthy protein levels [1][3] - The company is working on disease-modifying treatments for a wide range of rare and prevalent genetic diseases, where increasing healthy protein levels may provide significant therapeutic benefits [3] Upcoming Event - Josh Mandel-Brehm, President & CEO of CAMP4, will present a corporate update at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 3:45 p.m. PST [1] - The event will be available for live webcast on CAMP4's investor relations page, with a replay archived for 30 days post-conference [2] Technology and Approach - CAMP4's proprietary RAP Platform™ enables the mapping of regRNAs and the generation of therapeutic candidates aimed at targeting regRNAs associated with genes involved in haploinsufficient and recessive partial loss-of-function disorders [3] - There are over 1,200 disorders where a modest increase in protein expression could have clinically meaningful effects [3]

Core Insights - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting antisense oligonucleotide (ASO) therapies to enhance gene expression and restore healthy protein levels [1][2] 2024 Key Highlights - 2024 was a transformative year for CAMP4, marked by a successful IPO, with gross proceeds of approximately $75.0 million from the sale of 6,820,000 shares at an initial price of $11.00 per share [5] - The company received Rare Pediatric Disease Designation and Orphan Drug Designation for its lead program CMP-CPS-001, aimed at treating urea cycle disorders (UCDs) [4][5] - The Phase 1 study of CMP-CPS-001 demonstrated favorable safety results, with all treatment emergent adverse events being Grade 1 (mild) or Grade 2 (moderate) [5] - CAMP4 was added to the Russell 2000® Index, enhancing its market visibility [4][9] - A new discovery program targeting a GBA1 regRNA for Parkinson's disease was initiated [4][9] Expected Milestones in 2025 - The company anticipates reporting Multiple Ascending Dose (MAD) safety and key biomarker data in the second half of 2025, which could facilitate the advancement of CMP-CPS-001 into a registrational Phase 2/3 trial in 2026 [2][4][9] - Initiation of GLP toxicity studies for the lead ASO candidate targeting neurodevelopmental disorders caused by SYNGAP1 mutations is planned for this year [9] - CAMP4 aims to expand its strategic partnerships to maximize the value of its RAP platform [9]

Core Viewpoint - CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing regRNA-targeting therapeutics aimed at restoring healthy protein levels in various genetic diseases [1]. Group 1: Conference Participation - CAMP4 will present and hold one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference from December 3rd to 5th, 2024 [1]. - The presentation is scheduled for December 5, 2024, from 1:00 to 1:25 PM ET, and a live webcast will be available on the company's investor relations website [2]. Group 2: Company Overview - CAMP4 is developing disease-modifying treatments for over 1,200 genetic diseases by amplifying healthy protein levels through its proprietary RAP Platform™, which targets regRNAs that regulate gene expression [4]. - The company's approach involves using ASO drug candidates to amplify mRNA, which may provide therapeutic benefits in conditions characterized by haploinsufficiency and recessive partial loss-of-function disorders [4].